Assessed for eligibility (n=24)
- Excluded (n=5)
  - Less than 5 participants in an unit (n=1)
  - Lack of virological confirmation of influenza in the ILI index case (n=2)
  - >48 hours having elapsed since the start of the outbreak (n=2)
- Analysis (n=6)
  - Excluded from analysis because PEP study medication was not delivered according to protocol (n=1)

Excluded from analysis because PEP study medication was delivered not according to protocol (n=1)

Analysed (n=6)
- Index patient (n=11)

Randomised (n=17)
- Allocated to intervention (n=10)
  - Received oseltamivir as PEP (n=7)
  - Received placebo as PEP (n=3)
- Analysis (n=8)
  - Excluded from analysis because ILI symptoms at the first day of the study (n=1)
  - Excluded from analysis because PEP study medication was not delivered according to protocol (n=1)

Virological analysis of 3/3 secondary ILI and 29/33 at end of PEP

Follow-up (n=7)
- Not lost to follow-up (n=41/43)
  - Died (n=2)

Allocated to intervention (n=54)
- Received oseltamivir as PEP (n=43)
  - Index patient (n=11)
- Analysis (n=63/71)
  - Excluded from analysis because PEP study medication was delivered not according to protocol (n=7)
  - Excluded from analysis because ILI symptoms at the first day of the study (n=1)

Virological analysis of 8/9 secondary ILI and 39/54 at end of PEP

Follow-up (n=10)
- Not lost to follow-up (n=71/73)
  - Discontinued PEP (n=1), day 4
  - Discharged (n=1), day 5

Allocated to intervention (n=86)
- Received placebo as PEP (n=73)
  - Did not receive placebo as PEP, because of an index case (n=13)
- Analysis (n=63/71)
  - Excluded from analysis because PEP study medication was delivered not according to protocol (n=7)
  - Excluded from analysis because ILI symptoms at the first day of the study (n=1)

Virological analysis of 8/9 secondary ILI and 39/54 at end of PEP

Allocation

Excluded (n=239)
- Declined to participate (n=239)

Randomised (n=140)

Follow-Up

Not lost to follow-up (n=41/43)
- Died (n=2)

Allocated to intervention (n=54)
- Received oseltamivir as PEP (n=43)
  - Index patient (n=11)

Analysis

Analysed (n=63/71)
- Excluded from analysis because PEP study medication was delivered not according to protocol (n=7)
  - Excluded from analysis because ILI symptoms at the first day of the study (n=1)

Virological analysis of 8/9 secondary ILI and 39/54 at end of PEP

Follow-up (n=10)
- Not lost to follow-up (n=71/73)
  - Discontinued PEP (n=1), day 4
  - Discharged (n=1), day 5

Allocated to intervention (n=86)
- Received placebo as PEP (n=73)
  - Did not receive placebo as PEP, because of an index case (n=13)

Allocation